

James Clarke<sup>1</sup>, Nikunj Kumar Patel<sup>1</sup>, Sebastian Polak<sup>1,2</sup>

<sup>1</sup>Certara UK Limited, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ, United Kingdom, <sup>2</sup>Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland

## Background

A mechanistic Physiologically Based Pharmacokinetic (PBPK) Model describing diffusion and absorption processes in the dermis has been presented previously (Clarke 2018). The Depth Resolved Dermis Model (DRDM) has been verified for six compounds in the literature for which depth-resolved concentration profiles in the dermis were available. One important aspect of this model is its ability to accurately predict the diffusion of small drug molecules in the dermis. As part of the model development, a new physiologically based, bottom-up approach for predicting the effective diffusivity in the dermis was developed.

## Methods

The effective diffusion of a molecule can be described by the weighted sum of the diffusion of its unbound form, and that of its bound form. Therefore this model requires three pieces of information:

- $D_{unbound}$  = The diffusivity of the unbound drug in dermis interstitial fluid
- $D_{bound}$  = The diffusivity of albumin bound drug in dermis interstitial fluid
- $f_{u_{ISF}}$  = Fraction unbound to albumin in the dermis interstitial fluid

These parameters can then be used to predict the effective diffusivity of the drug in the dermis using Equation 1.

$$D_{Dermis} = f_{u_{ISF}} * D_{unbound} + (1 - f_{u_{ISF}}) * D_{Bound} \quad (1)$$

### $D_{unbound}$

The diffusivity of an unbound molecule in the interstitial fluid (ISF) can be predicted using the Wilke-Chang equation (Equation 2).

$$D_{unbound} (cm^2/s) = \left( \frac{7.4 * 10^{-10} * T_{Dermis} * (MW\phi_{ISF})^{0.5}}{\eta_{ISF} * V_A^{0.6}} \right) \quad (2)$$

Where:

$T_{Dermis}$  = Absolute Temperature in the Dermis Value = 310.15 K

$MW\phi_{ISF}$  = Solvent Molecular Weight \* Association parameter (assumed the same as water);

Value = 40.68 Da

$\eta_{ISF}$  = Viscosity of ISF (assumed the same as lymph measured by Bouta et al., 2014);

Value = 0.0181 dyne × s/cm<sup>2</sup>

$V_A$  = Molar Volume of the Molecule (predicted from MW by method described in Ibrahim et al., 2012).

## Methods

### $D_{Bound}$

The diffusion of bound drug was taken to be the same as the effective diffusivity of albumin through interstitium (Nugent and Jain, 1984)(Nugent and Jain, 1984)(Fox and Wayland, 1979). Crucially this effective diffusivity is around 13-fold slower than the aqueous diffusivity of albumin.

Under the assumption that the molecule is sufficiently small that the effect on diffusion caused by its binding is negligible; Value = 0.000216 cm<sup>2</sup>/h

### $f_{u_{ISF}}$

The fraction of drug unbound to albumin in the interstitial fluid of the dermis can be predicted by Equation 3.

$$f_{u_{ISF}} = \frac{1}{1 + \frac{[P]_{Dermis}}{K_D}} \quad (3)$$

$[P]_{Dermis}$  = The abundance of albumin in the dermis ISF; Value = 458.1 μM (Bert et al., 1986)

$K_D$  = The affinity constant between the drug and albumin. This can be calculated by rearranging Equation 3 and replacing  $f_{u_{ISF}}$  and  $[P]_{Dermis}$  with values for plasma, where measured values of  $f_{u_{plasma}}$  are available.

Data on fraction unbound to albumin for the relevant drugs was collected, where multiple measurements were available, preference was given as such:

$$f_{u_{Dermis}} > f_{u_{2\% \text{ solution}}} > f_{u_{4\% \text{ solution}}} > f_{u_{plasma}} > f_{u_{predicted}}$$

For the latter three cases,  $f_u$  values were converted to  $f_{u_{Dermis}}$  using Equation 3.

A database of effective diffusivity values estimated experimentally was collated (Kretsos et al., 2008)(Anissimov and Roberts, 2011)(Ibrahim and Kasting, 2010) which included 34 observations.

These values were compared against the values predicted with this bottom-up approach. The quality of prediction was assessed by linear regression and Normalised root mean square error (NRMSE), normalised by max-min of the observed data.

## Results


A plot of Measured vs Predicted effective diffusivity values with a regression line can be seen in Figure 1.

Figure 1(a) shows the full data set of 34 observations, Points in Red represent data from (Tojo et al., 1987), which were excluded from the analysis because these values were obtained from 'stripped skin' i.e., skin that still had a large portion of viable epidermis intact. It is clear that these data points are not representative of diffusion in the dermis, therefore they were not included in the analyses, leaving 27 observations. A linear regression analysis found an R<sup>2</sup> of 0.94 with a slope 1.12. The NRMSE was 9.4%.

## Results

Figure 1(b) shows a dataset subset to only include observations for which a measured value of fraction unbound to albumin was available. A linear regression analysis found an R<sup>2</sup> of 0.98 with a slope 1.12. The NRMSE was 6.6 %.

Figure 1 – Measured vs Predicted diffusivity values. Red points were not included in the regression analysis



## Conclusions

This bottom-up approach to predicting drug diffusion in the dermis showed good predictive power.

This work suggests that a major determinant of drug diffusion in the dermis is its albumin binding affinity.

This model, due to its physiologically based methodology could be leveraged to predict the effect of skin disease upon the diffusion of drugs in the dermis. For example in psoriasis where the albumin content of the dermis ISF has been shown to be decreased (Staberg et al., 1983).

## References

- CLARKE, J. F., PATEL, N. & POLAK, S. 2018. Predicting Depth Resolved Concentrations in the Dermis using PBPK modelling: Design, development and verification of the model with five drugs. *AAPS PharmSci* 360.
- WILKE, C. R. & CHANG, P. 1955. Correlation of diffusion coefficients in dilute solutions. *AIChE Journal*, 1, 264-270.
- BOUTA, E. M., WOOD, R. W., BROWN, E. B., RAHIMI, H., RITCHLIN, C. T. & SCHWARZ, E. M. 2014. In vivo quantification of lymph viscosity and pressure in lymphatic vessels and draining lymph nodes of arthritic joints in mice. *The Journal of Physiology*, 592, 1213-1223.
- IBRAHIM, R., NITSCHKE, J. M. & KASTING, G. B. 2012. Dermal clearance model for epidermal bioavailability calculations. *J Pharm Sci*, 101, 2094-108.
- NUGENT, L. J. & JAIN, R. K. 1984. Plasma pharmacokinetics and interstitial diffusion of macromolecules in a capillary bed. *Am J Physiol*, 246, H129-37.
- NUGENT, L. J. & JAIN, R. K. 1984. Extravascular diffusion in normal and neoplastic tissues. *Cancer Res*, 44, 238-44.
- FOX, J. R. & WAYLAND, H. 1979. Interstitial diffusion of macromolecules in the rat mesentery. *Microvascular Research*, 18, 255-276.
- BERT, J. L., PEARCE, R. H. & MATHIESON, J. M. 1986. Concentration of plasma albumin in its accessible space in postmortem human dermis. *Microvascular Research*, 32, 211-223.
- ANISSIMOV, Y. G. & ROBERTS, M. S. 2011. Modelling dermal drug distribution after topical application in human. *Pharm Res*, 28, 2119-29.
- IBRAHIM, R. & KASTING, G. 2010. *Improved Method for Determining Partition and Diffusion Coefficients in Human Dermis*.
- TOJO, K., CHIANG, C. C. & CHIEN, Y. W. 1987. Drug permeation across the skin: effect of penetrant hydrophilicity. *J Pharm Sci*, 76, 123-6.
- STABERG, B., WORM, A. M., KLEMP, P. & ROSSING, N. 1983. Transvascular transport and distribution of fluid and protein in psoriasis. *J Am Acad Dermatol*, 8, 193-9.